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Abstract: Spinal muscular atrophy (SMA) is an autosomal recessive condition that results in 
pathological deficiency of the survival motor neuron (SMN) protein. SMA most frequently presents 
itself within the first few months of life and is characterized by progressive muscle weakness. As a 
neuromuscular condition, it prominently affects spinal cord motor neurons and the skeletal muscle 
they innervate. However, over the past few decades, the SMA phenotype has expanded to include 
pathologies outside of the neuromuscular system. The current therapeutic SMA landscape is at a 
turning point, whereby a holistic multi-systemic approach to the understanding of disease 
pathophysiology is at the forefront of fundamental research and translational endeavours. In 
particular, there has recently been a renewed interest in body composition and metabolism in SMA 
patients, specifically that of fatty acids. Indeed, there is increasing evidence of aberrant fat 
distribution and fatty acid metabolism dysfunction in SMA patients and animal models. This review 
will explore fatty acid metabolic defects in SMA and discuss how dietary interventions could 
potentially be used to modulate and reduce the adverse health impacts of these perturbations in 
SMA patients. 
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1. Introduction 
Spinal muscular atrophy (SMA) is a debilitating neuromuscular disorder, which 
predominantly affects children within the first months of life, affecting 1:10,000 live births 
[1]. SMA primarily impacts alpha motor neurons in the spinal cord, leading to their death, 
resulting in muscle wasting, hypotonia and hyporeflexia [2]. 
SMA pathology is caused by a deficiency in the survival motor neuron (SMN) 
protein. In >90% of SMA patients, there is homozygous loss of the gene encoding this 
protein: survival motor neuron 1 (SMN1) [3,4]. This gene was identified in 1995 on the 
telomeric region of chromosome 5 [5]. Interestingly, this stretch of genome contains a 
preserved inverted duplication mutation such that there is a near identical gene located 
closer to the centromere, which is named SMN2 [4]. This is a unique feature and in some 
ways represents the existential cause of SMA, as without SMN2, humans would not live 
to develop the condition. There are only five nucleotides that are different between the 
paralogues, which does not alter coding for amino acids but does affect pre-mRNA 
splicing [6]. The substitution of a C for a T in the 6+ position of exon 7 of the SMN2 gene 
[7] primarily results in the loss of a splicing enhancer, SF2/ASF [8], leading to the 
skipping of exon 7 in around 90% of transcripts. The truncated protein (SMNΔ7) 
produced is unstable and less functional compared to the full-length version [9], but is not 
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considered a negative dominant. The remaining 10% of transcripts are structurally and 
functionally normal. SMN2 is extremely important in the context of SMA as gene copy 
number is a positive modifier of the condition. Indeed, it has been shown that disease 
severity is inversely proportional to the number of SMN2 copies [10]. In essence, this 
means that the loss of SMN1 is compensated for, to a greater or lesser extent, by the 
number of SMN2 copies a person possesses and thus the amount of SMN that can still be 
produced. SMA, therefore, results from the complete loss of SMN1 and the concurrent 
retention of at least one copy of SMN2 (Figure 1). 
 
Figure 1. Genetics of spinal muscular atrophy (SMA). The SMN1 gene produces 100% full-length 
functional protein. The homologous SMN2 gene produces about 10% of full-length functional 
SMN protein and 90% of a truncated and rapidly degraded SMNΔ7 protein, due to a C to T 
substitution in exon 7. Healthy individuals retain copies of both SMN1 and SMN2 while SMA 
patients have a loss of SMN1 due to mutations and/or deletions. 
SMA is clinically classified into types based on severity and age of onset, whereby 
SMN2 gene copy number is the major disease modifier, as a greater number of SMN2 
copies results in a larger amount of functional full-length SMN protein being produced 
[11]. Type I, also known as Werdnig-Hoffman disease, is the most severe and common 
form of the condition, accounting for 50% of cases [2]. Type I presents at <6 months of age 
and these babies are unable to sit up independently, the disease usually leading to a 
premature death before they reach their second birthday [12]. Type II is an intermediate 
form of the disease with an onset between 6 and 18 months and a reduced lifespan [13]. 
Patients with this form do not gain the ability to walk and even though they are usually 
unable to stand without support, some can stand independently [2]. However, these 
motor aptitudes are not necessarily maintained as although gain of functions are 
observed, over time, there is a net loss of function for all SMA patients [14]. Type III SMA 
occurs from 18 months onwards [15]. Type III children will at some point be able to walk 
and have a normal life expectancy, though with varying degrees of disability [16]. Type IV 
SMA is an adult onset classification of the disease, whereby patients begin to exhibit 
muscle weakness between their 30s and 40s, retain the ability to walk and have a typical 
lifespan [2,17]. Type IV is the rarest form of SMA and accounts for <5% of cases [18]. In 
general, type I patients have 1–3 SMN2 copies, type II patients 2–4 copies, type III patients 
2–5 copies and type IV patients 4–6 copies [19]. The overlap of copy number between 
clinically distinct phenotypes does however suggest the presence of additional non-SMN 
modifiers [19]. 
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SMN is ubiquitously expressed [20] and the cellular machinery it is involved with is 
crucial to the working of all cell types [21]. Previously, the rhetoric behind SMA focused 
on why only motor neurons are affected by the loss of a protein that is present in every 
cell. Over the past few decades, the picture of SMA has been changing, with expanding 
recognition of non-neurological pathologies that can be attributed to SMN deficiency [22]. 
Of these, fatty acid oxidation metabolism defects have frequently been reported in both 
earlier case reports and more recent studies in SMA animal models and patients. Fatty 
acids have many important functions in the body as they are a principal source of energy 
[23]. Indeed, fatty acids are crucial components of the human body, whereby they have 
structural, functional and biological roles such as being an important constituent of the 
cell membrane as well as acting as a crucial energy source for the heart, skeletal muscle 
and kidney [23]. Their metabolism also produces a significant amount of adenosine 
triphosphate (ATP), not only in the postabsorptive and fasted states when glucose supply 
is limited but also when glucose is abundantly available [23]. In this review, we will provide 
an up-to-date assessment of fatty acid metabolism defects in SMA as well as discuss the 
interactions between body composition, nutrition and metabolism in relation to SMA pathology. 
2. Body Composition of SMA Patients 
By conventional body mass index (BMI) measurements, SMA patients often appear 
normal or underweight [24]. However, when subject to more rigorous anthropometric 
testing, there appears to be a recurring incidence of increased adiposity within the SMA 
population. Indeed, in a study of 34 type I patients, aged between 1 and 36 months, a 
significant increased fat mass compared to age-matched controls was observed, despite 
35% of the SMA cohort meeting the criteria for failure to thrive [25]. Similar findings 
were reported when comparing type I and II children [24], whereby the mean BMI z score 
(BMI adjusted for age) was −6.3 and −2.1 for SMA type I and type II respectively, values 
that would be interpreted as distinctly undernourished. According to their BMI, none of 
the children with type I and II SMA were overweight or obese, yet in comparison to age 
and sex-matched children, they had on average 20% more fat [24]. An additional study on 
type II and III patients concluded that while they displayed a significant reduction of lean 
mass, aligned with the muscle wasting that typifies SMA, they also had significant 
elevation in absolute fat mass [26]. Indeed, in the study group of 25 children, 10 patients 
(40%) had a fat mass index (FMI) >85th percentile that indicates “at risk of overweight” 
and 5 patients (20%) had an FMI >90th percentile indicating “overweight”. This is in 
accordance with the Centre for Disease Control and Prevention (CDC)’s weight 
classifications. These findings highlight the fact that BMI testing is not a sufficient tool to 
estimate adiposity in SMA patients and that for the most part, there is an inverse 
relationship between the BMI and FMI of SMA patients. 
One possible contributor to the increased fat mass in SMA patients is an imbalance 
between dietary intake and energy expenditure. The degenerative nature of SMA makes 
this scenario quite plausible as progression of the disease leads to increasing 
immobilisation. In 2015, a retrospective study was conducted based on clinical data from 
60 SMA patients (types I, II and III) in order to assess nutrient intake and establish 
nutritional status [27]. Anthropometric data was analysed from two visits made 2 years 
apart on average. At initial assessment, 9 children (15%) were considered to be 
malnourished, based on weight for age z scores (WAZ) out with ±2. However, there was 
no discrimination between malnourishment due to overfeeding (WAZ >+2) and 
malnourishment due to underfeeding (WAZ <−2). In the subgroup of 17 device-fed 
patients, 6 (35%) were considered optimally fed, 5 (30%) overfed and 6 (35%) underfed. 
There is therefore little clarity regarding the nutritional requirements for SMA patients as 
there are cases of both under and overfeeding. It is additionally worth noting that the 
methods in this study included using the “Schofield equation” to estimate basal metabolic 
rate, which has been shown to overestimate resting energy expenditure (REE) by between 
11% [24] and ~19% [28] compared to REE measured by indirect calorimetry. Thus, SMA 
Brain Sci. 2021, 11, 131 4 of 15 
 
patients reported as being underfed may in fact not have been and the incidence of 
overfeeding may indeed be larger than reported. This could have particular significance 
with regard to the reported increased fat mass in SMA, as lack of accuracy surrounding 
assessments directly limits the ability to make appropriate dietary recommendations, 
which may lead to energy imbalance. Additionally, energy requirements based on the 
Schofield equation were used on the cohort as a whole, as it was assumed that activity 
levels would not vary much between patients. However, as described above, motor 
capabilities within types I-III SMA patients can in fact vary quite extensively [29]. 
Furthermore, in SMA patients, caloric intake has been shown to correlate with motor skills 
measured by the Hammersmith Motor Scale, and there may be differences between SMA 
subtypes based on function and ambulation [26]. Thus, the increased fat mass prevalent 
within SMA children may be due to a lack of understanding of how best to manage dietary 
requirements. However, it is also worth considering whether increased fat mass could be 
due to mechanistic defects in fat metabolism, specifically fatty acid oxidation, which could 
have a significant repercussion on whole-body homeostasis and health of SMA patients. 
3. Fatty Acid Oxidation and Metabolism 
3.1. Basics of Fatty Acid Oxidation and Metabolism 
Fats have multiple roles within the body, from membrane components to signalling 
molecules, but they are most commonly associated with energy metabolism. In the form 
of triglycerides, they are the primary source of energy storage as they contain a higher 
energy content per gram (9 kcal/g) than both proteins and carbohydrates (4 kcal/g) [30]. 
In the fasted state, adipose tissue releases triglycerides (fatty acids and glycerol) for 
utilisation in energy production [31]. Glycerol can be converted to produce glucose and 
fatty acids are progressively broken down via oxidation, of which there are three types 
(alpha, beta and omega), to ultimately form acetyl-CoA. Both glucose and acetyl-CoA then 
enter the citric acid cycle [32]. 
Oxidation of fatty acids predominantly occurs by beta oxidation in the matrix of 
mitochondria, following activation of fatty acids through thioester bonding with Co-
enzyme A (CoA). This process removes a hydroxyl group from the fatty acids, forming 
highly polar thioesters called acyl-CoA molecules. Long chain acyl-CoA molecules (10+ 
carbons) cannot freely pass through mitochondrial membranes and require shuttling in 
the form of carnitine derivatives, referred to as acylcarnitines or esterified carnitines, 
whereby an ester bond links the fatty acyl-CoA to the carnitine molecule [33]. Once inside 
the mitochondria, fatty acids follow the beta oxidation pathway, which essentially 
comprises a repeating sequence of 4 reactions catalysed by acyl-CoA dehydrogenase, 
enoyl-CoA hydratase, hydroxy acyl-CoA dehydrogenase, and ketoacyl-CoA thiolase, 
respectively, cleaving 2 carbons from the acyl chain each time to produce acetyl-CoA 
(Figure 2). 
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Figure 2. Schematic diagram of mitochondrial fatty acid entry and beta oxidation. Long chain fatty 
acid (LCFA) is activated by bonding with CoA upon cell entry. Acyl-CoA dehydrogenase (ACAD) 
catalyzes this first reaction. This molecule, now an acyl-CoA, is shuttled through the 
mitochondrial membrane by forming an ester bond with carnitine, thus generating acylcarnitine. 
Once inside the mitochondria, acylcarnitine is broken down to produce free carnitine, which can 
be recycled to shuttle in further fatty acids in the mitochondria. The long chain acyl-CoA 
generated is then oxidised to produce acetyl-CoA, a process catalysed by mitochondrial 
trifunctional protein (MTP). Acetyl-CoA can be utilised in the tricarboxylic acid cycle (TCA) cycle 
or participate in ketogenesis. 
While the majority of beta oxidation takes place in the mitochondria, additional beta 
oxidation also occurs inside peroxisomes. Peroxisomes are double membrane-bound 
organelles found in eukaryotic cells and they are responsible for the catabolism of various 
types of molecules as well as the exclusive site of alpha oxidation of fatty acids [34] that 
otherwise cannot directly undergo beta oxidation. Alpha oxidation cleaves only one 
carbon at a time and is utilised for the breakdown of 3-methyl branched fatty acids [35] 
(Figure 3). For very long chained fatty acids (VLCFAs, >22 carbons), omega oxidation that 
occurs in the endoplasmic reticulum (ER), converts these molecules into dicarboxylic acids 
(DCAs), which can then undergo beta oxidation in the peroxisome [36] (Figure 3). Omega 
oxidation accounts for only a small proportion of all fatty acid oxidations [37] but 
compensates when there is defective/deficient beta oxidation, leading to an accumulation 
of DCAs, the excess of which is excreted into the urine. DCAs are an important, though 
often non-specific marker for fatty acid oxidation disorders [38]. 
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Figure 3. Schematic diagram of alpha and omega oxidation. Very long chain fatty acids (VLCFAs) 
either go through peroxisomal alpha oxidation or omega oxidation in the endoplasmic reticulum 
(ER). The latter produces dicarboxylic acids (DCAs) that undergo peroxisomal beta oxidation, 
produce shortened acyl-CoAs that then go through mitochondrial beta oxidation. 
3.2. Fatty Acid Oxidation and Metabolism Defects in SMA 
One of the earliest accounts associating SMA with potential fatty acid metabolic 
abnormalities is a case report by Kelley and Sladky in 1986 [39], where a type II male 
hospitalised for respiratory distress was noted to excrete abnormally high levels of 
medium chain DCAs in proportion to 3- hydroxybutyrate (BHB). BHB is a ketone body 
that, alongside DCAs, is normally produced in states such as fasting or catabolic illnesses 
when there is decrease in glucose levels in the blood and subsequent increase in circulating 
fatty acids [40]. 
Fatty acid metabolism defects have since been regularly reported in SMA such as in a study 
of 14 SMA patients that displayed dicarboxylic aciduria, high excretion of urinary 
acylcarnitines and carnitine deficiency in both muscle and serum [41]. A deficiency in 
acyl-CoA dehydrogenase, the enzyme responsible for the first step of beta oxidation, was 
also noted. Subsequent studies helped to provide additional mechanistic insight into fatty 
acid metabolism defects and dicarboxylic aciduria in SMA children [42]. Indeed, the 
aciduria of small and medium chained fatty acids was most evident in SMA type I patients 
compared to SMA type II and III patients, suggesting that metabolic abnormalities vary 
with SMA severity [42]. In this same study, five children (2 type I, 2 type II and 1 type III) 
provided muscle biopsies for further fatty acid oxidation analyses [42]. Specifically, the 
activity of 5 key enzymes involved in fatty acid metabolism regulation (long-chain 3-
hydroxyacyl-CoA dehydrogenase (LCHAD), short-chain 3-hydroxyacyl-CoA 
dehydrogenase (SCHAD), 3- ketothiolase, acetoacetyl-CoA thiolase and enoyl-CoA 
hydratase) was analysed. All of these enzymes are involved in beta oxidation except for 
acetoacetyl-CoA thiolase, which is implicated in the production of ketone bodies. 
Interestingly, in all 5 patients, the activity of enoyl-CoA hydratase was normal, while all 
other enzymatic activity was significantly reduced. Free and acylcarnitine levels were also 
assessed and significant elevations in the percentage of esterified carnitine (i.e., fatty acyl-
CoA-carnitine ester bonds) were observed in SMA patients, the highest of which occurred 
in the youngest type I and type II children [42], suggesting aberrant fatty acid oxidation 
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processes in SMA patients. However, in this study, it is unclear where the normal range 
of values originated from and from which state (fasting or fed). In addition, the time 
elapsed between the patient eating and the test being performed was not mentioned. 
However, in a subsequent study, increased acylcarnitine levels were also observed in 
SMA patients (>50% esterified) compared to normal values of 10–25% (fed) and 30–50% 
(fasting) [43]. 
Fasting and non-fasting fatty acid profiles revealed similar abnormalities in serum 
and urine samples from 50 SMA patients when compared to healthy controls and infants 
suffering from a denervating condition that is not caused by loss of SMN [44]. The SMA 
patients were categorised into “severe infantile” and “juvenile chronic”, which 
presumably refers to type I and types II/III, respectively. In the fasted state, when 
perturbations are most likely to become evident, significantly higher levels of dodecanoic 
acid (C12), saturated medium-chain fatty acid with a 12-carbon chain, were found in 
severe SMA patients compared to the other groups, including the defined “disease 
control” and “normal control” groups, who demonstrated the typical and expected 
increase of C12 in the plasma of fasted healthy children [45]. When glucose levels fall, such 
as in fasting states, there is an expected switch from glucose to fatty acid metabolism [46]. 
A build-up of C12 suggests that there is either a block of further breakdown past 12 
carbons by the LCHAD/trifunctional enzyme complex or that transport of these long chain 
fatty acids into the mitochondrial matrix is impaired. Whereas longer chained fatty acids 
will undergo carnitine esterification at high concentrations and shorter chained fatty acids 
are able to diffuse into cells, C12 chain length is such that it will not readily do either and 
so remains in the serum [47]. Furthermore, urinary samples from these SMA patients 
showed increases in non-specific DCAs. In fact, the ratio of DCA:ketones in infantile SMA 
is strikingly similar to that of patients with known fatty acid oxidation defects [44]. 
Additionally, in this study, there is supporting evidence for the hypothesis that metabolic 
dysfunction reflects SMA severity as the DCA:ketone ratios for all the severe SMA 
children under 10 months old were decidedly abnormal while type II infants of a similar 
age had ratios that were well within the normal limits [44]. Three infantile SMA patients 
in this study who survived to 32, 54, and 63 months were tested a second time. 
Interestingly, the C12 levels recorded at the older age were lower than the first 
measurements and similar to the range in control groups, suggesting an age-dependent 
influence on metabolic perturbations, perhaps due to developmental functions of SMN. 
There is therefore consistent evidence of disruption of fatty acid metabolism in SMA 
patients (Figure 4). What is not totally clear, however, is the cause of these metabolic 
perturbations. Whereas increased fat mass in SMA children points towards the need to 
better quantify a recommended dietary intake, the prospect of fatty acid oxidation defects 
suggests that the components of that diet may also need to be more carefully considered 
in SMA. 
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Figure 4. Summary of fatty acid oxidation (FAO) defects in SMA. Mitochondrial trifunctional 
protein (MTP), acyl carnitine dehydrogenase (ACAD). 
4. Nutrition and Fatty Acid Metabolism in SMA 
4.1. Dietary Approaches Evaluated in SMA Mouse Models 
As discussed above, there is a need to better understand the relationship between 
fatty acid metabolism defects, aberrant fat accumulation and diet in SMA. SMA mouse 
models are well established, display the canonical hallmarks of the disease and have been 
invaluable to our understanding of pathological mechanisms and therapeutic 
development [48]. Notably, SMA mouse models of varying severities and genetic 
backgrounds display significant fatty acid metabolism defects similar to those reported in 
SMA patients such as microvesicular steatosis, high levels of triglycerides and long chain 
fatty acids length alterations [49]. 
The importance of nutrition and its impact on SMA disease progression was first 
highlighted following the observation that severe SMA mice lived 2–4 days longer when 
maintained on a 9% fat diet compared to a 5.2% fat diet [50]. Interestingly, as SMA mice 
die before weaning age, the benefits of the dietary interventions were dependent on being 
transmitted by the maternal milk. As part of the SMA phenotype in mice includes poorer 
feeding, the improvement in survival achieved by the higher fat diet may be because SMA 
mice achieved a greater calorific intake for less effort. In humans, however, some studies 
have found no direct association between maternal diet and fat content of milk [51] while 
others suggest some inter-relations that are perhaps dependent on the stage of milk 
production (i.e., colostrum vs transitional milk vs mature milk) [52]. 
Both 9% and 5.2% fat-containing diets were found to have no effect on spinal cord 
motor neuron loss, onset of body mass loss or overall body weight. There were however 
differences noted when looking at energy metabolites. In general, wild type (WT) mice 
had higher blood glucose levels than SMA mice. The 5.2% fat diet-fed mice (both WT and 
SMA) were found to have higher blood glucose than 9% fat diet-fed mice. Additionally, 
ketone levels were higher in SMA mice compared to WT animals and this was most 
evident in SMA mice fed the 5.2% fat diet. These results suggest that some dietary 
component is affecting the SMA phenotype, which may be fat content but also additional 
dietary elements that differed between both diets (e.g., protein, individual amino acids, 
fatty acids). 
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In a more recent study, a high-fat diet (HFD) (60% Kcal fat) and low-fat diet (LFD) 
(10% Kcal fat) were compared to normal chow (NC) in SMA mice [53]. Similar to above, 
the diets were administered to the dams until the pups could freely feed on their own. 
However, it is unknown whether the full extent of the nutritional content of each diet was 
carried in the milk of the dams to the pups. Nevertheless, introduction of the LFD doubled 
the life expectancy of SMA mice in comparison to normal chow, while HFD did not lead 
to any improvements. Interestingly, weight, Smn levels and hepatic fat content were only 
changed to a limited extent regardless of diet. In addition, liver damage was reduced in 
SMA mice fed the LFD compared to those receiving NC, suggesting that LFD may restore 
appropriate proportions of energy substrates by reducing circulating fats and increasing 
glucose. More importantly, LFD led to reduced plasma ketones, implying reduced beta-
oxidation and a lower reliance on fatty acids as an energy source. From these results, it 
appears that diet modulation aimed at decreasing fatty substrate availability diminishes 
the load on fatty acid oxidation processes and ameliorates overall health. 
The contradictory conclusions between both studies, whereby one favours a HFD 
[50] and the other a LFD [53], makes it hard to conclude which type of diet should be used 
for SMA. The opposing results may be from the individual dietary compositions within 
the diets, variability in fat content used, disease severity of mouse models and/or genetic 
backgrounds. Therefore, further investigations are required to fully appreciate which 
dietary components are key to improving fatty acid metabolism and overall health in 
SMA. 
While diet alone can have a profound effect on the health of an organism, in the 
context of medical care, it is also very important to consider its interaction with a drug 
treatment. Indeed, the bioavailability and pharmacokinetics of pharmacological 
compounds are especially influenced by diet and body composition [54,55]. D158944, a 
member of the quinazoline family, which promotes inclusion of exon 7 in SMN2 
transcripts, was administered to mice either on a Picolab20 or Harlan diet [50]. A 15% 
increase in lifespan was observed in mice treated with D158944 and mice fed the 
PicoLab20 diet lived longer than those reared on Harlan. Interestingly, D158944 levels 
were 32% higher in the brains of mice fed the PicoLab20 diet compared to those on the 
Harlan diet, suggesting that diet can impact the bioavailability of the drug levels in the 
central nervous system (CNS). 
A further example of drug and diet interaction in SMA mice is demonstrated in a 
study evaluating the therapeutic potential of Trichostatin (TSA), a histone deacetylase 
inhibitor [56]. This drug itself had proven promising by lengthening the mean lifespan of 
SMA mice. When combined with “aggressive nutritional support”, there was a 170% 
increase in survival of these SMA mice compared to the ones lacking the drug 
combination [57]. In addition, combining TSA and nutritional support improved the 
motor skills of SMA mice compared to animals only receiving nutritional support. 
Overall, while these studies in pre-clinical models clearly demonstrate a role for 
dietary interventions in the management of SMA symptoms and disease progression, 
there remains a lack of clear identification of the key specific dietary constituents and their 
levels. A better understanding of these components is essential for the development of 
nutritional guidelines for SMA patients [58]. 
4.2. Dietary Interventions in SMA Patients 
The current nutritional guidelines for SMA patients recommend dietary adjustments 
based on assessments of swallowing, dysphagia, weight, gastrointestinal function, 
glycaemic control and bone health [59] but not on fatty acid metabolism defects. 
However, patients and their families have nevertheless developed and adopted 
elemental diets. Elemental diets are amino acid based and low in fat feeds, meant to 
provide nutrition in the simplest elements to reduce the energy cost of digestion [60]. Diets 
such as these are thought to be beneficial in the background of poor digestion as they 
provide an easily digestible protein source and a low-fat content aids gastric motility and 
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reduces reflux [61]. Around half of the type 1 respondents to a nutritional survey reported 
gastric reflux and formula tolerance issues including gastrointestinal pain [62], making an 
elemental diet an attractive option. Indeed, between two visits made on average 18 months 
apart, the percentage of type I patients on an elemental diet increased from 38% to 68%, 
as reported in an observational study of caloric and nutrient intake [25]. Interestingly, 
some components of the elemental diet are similar to those in the LFD evaluated in SMA 
mice, suggesting that elemental diets could be positively modulating fatty acid defects in 
SMA patients [53]. 
It is important to note, however, that diets that are low in fat, such as elemental diets, 
are at risk of being deficient in essential fatty acids and may require particular attention 
to ensure an adequate intake of all nutrients and essentials acids [63]. In an observational 
study of caloric and nutrient intake [25], the number of diets [25] being supplemented 
with oil (15% at first visit, 38% at the second) is far less than the number using elemental 
formula (38% at visit 1 and 68% at visit 2). Furthermore, common nutrients at risk of 
deficiency due to inadequate intake (i.e., lower than recommended daily intake for age) 
were considered, and it was found that >25% of the cohort where deficient in alpha- 
linolenic fatty acid, linoleic fatty acid, vitamin A, vitamin D, vitamin E, vitamin K, folate, 
calcium, iron, and magnesium. Notably, the vitamins (A, D, E, K) listed here are all fat-
soluble vitamins. This further suggests that fat intake needs to be carefully managed. 
There is thus a clear need for more in-depth pre-clinical and clinical studies on 
dietary interventions in SMA to help inform clear and evidence-based nutritional 
guidelines aimed at reducing the impact of aberrant fatty acid metabolism on whole-body 
health. 
5. Conclusions 
The first account of fatty acid metabolism defects in SMA was in the late 1980s [39]. 
Since then, additional studies and reports have shed light on the relationship between 
SMA pathology and fatty acid abnormalities such as carnitine deficiencies, high levels of 
medium chain DCAs in proportion to BHB, acyl-CoA dehydrogenase deficiency and 
accumulation of dodecanoic acid C12 [40,41,46]. Notably, these fatty acid defects occur 
alongside an increased fat mass observed in SMA patients, in contradiction to BMI values 
and ongoing muscle wasting. Consequently, there is a need to better understand how 
nutrition and diet modulation (e.g., high-fat, low-fat and elemental diets) can impact SMA 
disease progression and fatty acid metabolism. 
Most tissues are involved in fatty acid metabolism, however, adipose tissue, skeletal 
muscle and liver are quantitatively more important than others. Each of these tissues has 
a store of triacylglycerol that can be mobilized in a regulated way to release fatty acids. 
There is a clear cooperation amongst these tissues and an overlap of fatty acid metabolism 
pathways in order to maintain whole body homeostasis [46]. Importantly, intrinsic defects 
in skeletal muscle, liver and adipose tissue have been reported in SMA mice and patients 
[49,64,65] and their impaired function could cause and/or amplify the fatty acid metabolic 
defects in SMA. Furthermore, it is possible that loss of SMN may directly impact fatty acid 
metabolism through its previously reported roles in mRNA splicing [66], actin dynamics 
[67,68], endocytosis [69], and key metabolic pathways (e.g., glucocorticoid-Krüppel-like 
15 [70]), which have all been implicated in regulating fatty acid and lipid metabolism [71–
76]. Therefore, a more thorough investigation of the intrinsic and extrinsic contributions 
of each of these tissues to fatty acid metabolism defects in SMA could help elucidate their 
respective roles. 
Whilst the present review focused on fatty acid metabolism, other metabolic 
pathways have been implicated in SMA pathology. Indeed, glucose metabolism defects 
such as fasting hyperglycemia, glucose intolerance and hyperglucagonemia have been 
observed in SMA mice and patients [77,78]. Moreover, perturbed amino acid metabolism 
has also been reported in SMA mice [70]. Finally, in addition to the strong evidence of 
disrupted fatty acid metabolism in SMA presented here, recent studies have shown a 
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strong susceptibility for SMA patients to develop dyslipidaemia accompanied with fatty 
liver disease [49]. Given the inter-relationship between metabolic pathways, it will be 
essential to understand what causes their dysregulation in SMA and how they may be 
influenced by each other and nutritional intake. 
From the studies presented here, it appears that both the severity of disease and age 
critically impact fatty acid metabolism defects in SMA patients, which should be taken 
into consideration when undertaking studies to establish nutritional guidelines. Of 
importance is that in the current therapeutic landscape of SMN-dependent therapies, 
patients are living much longer and reaching milestones never before seen [79]. 
Consequently, not only co-morbidities related to the development of impaired metabolic 
pathways, but also other perturbations related to puberty and aging should be taken into 
account when establishing dietary interventions. 
There is also significant evidence that, in addition to SMA, fatty acid metabolism may 
play a role in the pathophysiology of other neurodegenerative and neuromuscular 
disorders such as amyotrophic lateral sclerosis (ALS) [80], multiple sclerosis, Alzheimer’s 
disease and Parkinson’s disease [81]. Of particular interest in the present review are the 
fatty acid metabolism perturbations observed in patients with ALS, a motor neuron 
disease that shares several pathological similarities with SMA [82]. Alterations in fatty 
acid and lipid metabolism have been reported in neurons, skeletal muscle and serum of 
ALS pre-clinical models and patients, impacting energy use, structural integrity and key 
signaling pathways [80,83–86]. Notably, a recent genome-wide meta-analysis study found 
that the acyl-CoA synthetase long chain family member 5 (ACSL5) gene, whose protein 
regulates lipid and fatty acid metabolism pathways [87,88], was associated with ALS and 
its accompanying weight loss [89]. As such, several dietary interventions aimed at 
modulating fatty acid and lipid metabolism abnormalities (e.g., high caloric diet [90,91], 
ketogenic diet [92] and acetyl-L-carnitine supplementation [93]) have been evaluated in 
ALS pre-clinical models and patients, with varying success [80]. Therefore, a better 
understanding of fatty acid metabolism defects and the impact of dietary interventions in 
other neurodegenerative and neuromuscular disorders could significantly help advance 
mechanistic insights, therapeutic development and nutritional management for SMA 
patients. 
In conclusion, further work is needed to determine optimal dietary practices to 
support the quality of life and well-being of SMA patients [58], which can easily 
complement the SMN-dependent and -independent drug treatments currently approved 
or being evaluated for the treatment of this devastating neuromuscular disorder [19]. 
Indeed, future clinical investigations of fatty acid metabolism defects in SMA patients 
treated with SMN gene-based therapies will be essential to better understand the nature 
of the metabolic perturbations and the contribution of different CNS and peripheral 
tissues to the fatty acid metabolism defects. 
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